A phase I open label, dose escalation trial to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of CE-245,677, an oral TIE2 kinase inhibitor, in patients with advanced solid tumors

Trial Profile

A phase I open label, dose escalation trial to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of CE-245,677, an oral TIE2 kinase inhibitor, in patients with advanced solid tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Feb 2007

At a glance

  • Drugs CE 245677 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top